Abrocitinib is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis. To support the rigorous analytical requirements of pharmaceutical development, this… Read more



















Abrocitinib is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis. To support the rigorous analytical requirements of pharmaceutical development, this category provides a comprehensive selection of reference standards, including the active pharmaceutical ingredient, known process-related impurities, and metabolites. Laboratories utilize these compounds for precise impurity profiling, method validation, and routine quality control testing. The collection features essential materials such as desmethyl forms, diastereomeric impurities, and nitroso byproducts, which are critical for ensuring safety and regulatory compliance. Furthermore, researchers can access stable isotope labelled compounds, such as deuterium-labelled variants, which serve as internal standards for accurate quantification in mass spectrometry-based assays. These high-quality reference materials enable consistent performance in stability studies and the monitoring of pharmaceutical quality throughout the drug development lifecycle.